SABR Combined With Axitinib and Toripalimab for Oligometastatic Renal Cell Carcinoma

NCT07744932 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Oligometastatic Clear Cell Renal Cell Carcinoma

Interventions

DRUG: axitinib plus toripalimab
RADIATION: SABR

Sponsor

Hebei Medical University Fourth Hospital